Challenges in Oral Lipid-lowering Therapy: Position Document of the Spanish Society of Cardiology

详细信息    查看全文

• 作者：Manuel Anguita Sá ; nchez^a ; Almudena Castro Conde^b ; Alberto Cordero Fort^c ; Xavier Garcí ; a-Moll Marimó ; n^d ; Juan José ; Gó ; mez Doblas^e ; José ; R. Gonzá ; lez-Juanatey^f ; ^{jose.ramon.gonzalez.juanatey@sergas.es" class="auth_mail" title="E-mail the corresponding author} ; Rosa Marí ; a Lidó ; n Corbi^g ; José ; Luis Ló ; pez-Sendó ; n^b ; José ; Mostaza Prieto^h ; Luis Rodrí ; guez Padialⁱ
• 关键词：Lipids and ischemic heart disease ; PCSK9 inhibitors ; Consensus document
• 刊名：Revista Española de Cardiología (English Edition)
• 出版年：2016
• 出版时间：November 2016
• 年：2016
• 卷：69
• 期：11
• 页码：1083-1087
• 全文大小：401 K

文摘

Lipid-lowering therapy is one of the cornerstones of cardiovascular prevention and is one of the most effective strategies in the secondary prevention of ischemic heart disease. Nevertheless, the current treatment of lipid disorders, together with lifestyle changes, fails to achieve the targets recommended in clinical guidelines in a substantial proportion of patients. PCSK9 inhibitors have demonstrated safety and efficacy in the treatment of dyslipidemia. Due to their ability to reduce low-density lipoprotein cholesterol levels, these drugs have recently been approved for clinical use by Spanish regulatory agencies, with the aim of reducing cardiovascular risk in selected patient groups.